Clinical trials: Heartburn
Erosive Esophagitis, Heartburn
A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily
The primary objective is to determine the pharmacokinetics (PK) of vonoprazan in breast milk of healthy lactating women who have received vonoprazan administered once daily or vonoprazan 20 mg administered twice daily for 4…
- Conditions
- Erosive Esophagitis, Heartburn, Symptomatic Nonerosive Gasroesophageal Reflux Disease, Helicobacter Pylori Infection
- Trial name
- NCT06391177
- Testing
- Vonoprazan
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Phathom Pharmaceuticals, Inc.
Gastroesophageal Reflux Disease (GERD), Heartburn
Response to Supplement and Placebo in GERD
The purpose of this study is to investigate the effects of a widely available over the counter supplement marketed for heartburn symptoms on symptoms and health-related quality of life in patients with gastroesophageal reflux…
- Conditions
- Gastroesophageal Reflux Disease (GERD), Heartburn, Dyspepsia
- Trial name
- NCT01915173
- Testing
- Supplement, Expanded Interview, Standard Interview
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Beth Israel Deaconess Medical Center
Gastroesophageal Reflux Disease, Dyspepsia
Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study
This study is being conducted to provide evidence that Compound Sodium Alginate Double Action Chewable Tablets are effective in managing the symptoms of heartburn, acid regurgitation and dyspepsia in patients with…
- Trial name
- NCT01869491
- Testing
- Compound Sodium Alginate Double Action Chewable Tablets
- Where
- 2 sites in China
- Volunteers
- 1,107 people
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
Heartburn
A Study to Assess the Bioequivalence of Famotidine/Antacid Combination Tablets Compared to Famotidine/Antacid EZ Chew Tablets (0208C-145)(COMPLETED)
A study in 24 healthy subjects to assess the bioequivalence of Famotidine/Antacid EZ Chew tablet taken without water and with water compared to the Famotidine/Antacid tablet taken with water.
- Trial name
- NCT00944671
- Testing
- famotidine (+) calcium carbonate (+) magnesium hydroxide tablet, Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water, Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Caffeine Dependence, Anxiety
Remote Guided Caffeine Reduction
The purpose of this online research study is to determine whether or not a gradual caffeine reduction program developed at Johns Hopkins can help people reduce their caffeine use.
- Conditions
- Caffeine Dependence, Anxiety, Sleep Disturbance, Gastrointestinal Dysfunction
- Trial name
- NCT04560595
- Testing
- Caffeine Reduction Manual
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
GERD Gastroesophageal Reflux Disease
The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease
This study compares mechanical sphincter augmentation (LINX Reflux Management System) to double-dose proton pump inhibitors (PPIs) for the management of reflux symptoms related to gastroesophageal reflux disease (GERD).
- Trial name
- CALIBER (NCT02505945)
- Testing
- Omeprazole, LINX Reflux Management System
- Where
- 21 sites in United States
- Volunteers
- 152 people
- Sponsor
- Torax Medical Incorporated
Gastroesophageal Reflux Disease (GERD)
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.
- Trial name
- NCT00394472
- Testing
- AZD3355
- Where
- 38 sites in Australia, Belgium and 6 more
- Volunteers
- 244 people
- Sponsor
- AstraZeneca
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
The primary objectives of this study are to assess the efficacy of vonoprazan (10 mg, 20 mg, and 40 mg On-Demand) compared to placebo (On-Demand) in relief of episodic heartburn over 6 weeks in participants with symptomatic…
- Trial name
- NCT04799158
- Testing
- Vonoprazan
- Where
- 63 sites in United States
- Volunteers
- 458 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
Heartburn
Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment
The purpose of this pilot study is to investigate the association between gastric acid suppression and relief of 24 hour heartburn following treatment with the proton pump inhibitor (PPI) drug esomeprazole in frequent heartburn…
- Trial name
- NCT02708355
- Testing
- Esomeprazole 20 mg
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Pfizer